Team 2018-11-28T18:50:43+00:00

We have extensive experience in all aspects of life sciences finance, including institutional sales, capital markets, investment banking, investor and public relations, sell-side analysis, and buy-side analysis. We have an equally strong foundation in the life sciences, which enables us to understand our clients’ R&D, regulatory, and commercial strategy. The combination of financial service and life science expertise allow us to best serve our clients’ needs.


Founding Partner

Andrew McDonald is an experienced healthcare investment professional with expertise in identifying transformative products and technologies in all stages of development. Andrew is a Founding Partner of LifeSci Advisors and LifeSci Capital. Prior to founding LifeSci, Andrew served as senior biotechnology analyst at Great Point Partners, a dedicated life science hedge fund. From 2004-2006, Andrew was Head of Healthcare Research and a Biotechnology Analyst at ThinkEquity Partners, a boutique investment bank. Prior to entering the financial services industry, Andrew was a medicinal chemist at Cytokinetics from 2001-2004, where he discovered and developed a promising anti-cancer agent now in clinical trials. Andrew began his pharmaceutical career as a medicinal chemist at Pfizer. Andrew received a Ph.D. in organic chemistry from UC Irvine and completed his B.S. in chemistry at UC Berkeley.

Founding Partner

Michael Rice has experience in portfolio management, corporate management, investment banking and capital markets. Prior to co-founding LifeSci Advisors and LifeSci Capital, Michael was the co-head of health care investment banking at Canaccord Adams, where he was involved in debt and equity financing. Michael was also was a Managing Director at Think Equity Partners where he was responsible for managing Healthcare Capital Markets, which included structuring and executing numerous transactions, many of which were firsts at ThinkEquity. Prior to that, Michael served as a Managing Director at Banc of America serving large hedge funds and private equity healthcare funds. Previously, he was a Managing Director at JPMorgan/Hambrecht & Quist.

United States

Account Managers

Account Manager

Hans Vitzthum has more than 25 years experience in institutional sales and healthcare research product management at Leerink Partners, Cowen & Co., and Lazard Capital Markets. Hans spent 12 years running the morning research call at two investment banks and has served as “Deal Captain” on more than 100 healthcare IPOs and secondary offerings. Hans has worked in healthcare research product management for the past 15 years and has developed extensive and long-standing relationships with the institutional investment community. Hans earned his Applied Baccalaureate from Columbia College.

Account Manager

Bob has over 25 years of experience as a buy-side analyst, portfolio manager, private equity investor and investment banker. He has extensive experience with health care companies, especially in the medtech, diagnostics and specialty pharma sectors. Bob focuses on providing CEOs and CFOs with strategic advice on key investor issues in order to enhance stock valuation through effective and compelling messaging and clear, consistent communications with institutional investors.Bob’s experience and perspective as an investor in public and private health care companies informs his strategic investor relations work for companies with market capitalizations from $100 million to over $50 billion. He has worked with medtech and spec pharma areas in providing ongoing investor relations advice as well as working on IPOs, follow-on offerings and equity-linked securities. In addition, Bob has advised companies in M&A transactions, dual track processes, and C-suite executive transitions. Before joining ICR, Bob was a Portfolio Manager and Senior Research Analyst at Principled Capital, a fund with $1.5 billion of AUM, for 10 years with responsibility for all health care investing. Prior to Principled, he was a Vice President at Warburg Pincus, one of the world’s largest private equity and venture capital firms, investing in health care. Bob was a member of the Board of Directors of The Medicines Company (MDCO) and Eurand international, which was acquired by Aptalis Pharma. He spent 15 years in investment banking, including serving as Managing Director in Health Care Finance Group at Bear Stearns & Co., having worked on capital markets and M&A transactions in excess of $5.0 billion. Bob earned a BA in Economics from Yale University and an MBA from Stanford University Graduate School of Business.

Jeremy brings 15 years of experience in healthcare, both as a sell-side analyst and as an investor relations advisor. Jeremy covered both medical devices and healthcare services as an analyst at such firms as Bank of America, Oppenheimer, and Cantor Fitzgerald, and he was quoted regularly in the financial press. As the founder of Whalebone Advisory, he built extensive experience developing and executing investor relations strategies for pre-IPO and publicly-traded healthcare companies and counseling senior executives on messaging to Wall Street, including guidance philosophy, earnings preparation, and corporate access plans. Jeremy presently serves on the boards of the Edgemont Community Council and of the Fraternal Order of Bendin-Sosnowicer. Jeremy earned an MBA in Finance from the Leonard N. Stern School of Business at New York University, a Diploma in Economics from the London School of Economics, and a BA in Economics and Political Science from the University of Chicago.

Dan Ferry joins LifeSci Advisors from Guggenheim Securities, where he specialized in connecting healthcare companies with buy-side investors, venture capitalists, KOLs, sell-side analysts, and the investment bank.  Mr. Ferry spent nearly 4 years at Guggenheim Securities putting together numerous non-deal roadshows, collecting feedback from investors, and helping shape investor outreach strategies.  Prior to Guggenheim, Mr. Ferry worked at Lazard Capital Markets where he participated in many successful healthcare company financings.  Over the course of his career, Mr. Ferry has developed long-standing relationships with the healthcare investment community.  Mr. Ferry received a BS in Finance from the University of Southern California.  He currently resides with his wife and three children in the Boston area.

Ashley R. Robinson has 20 years of experience in institutional equities, with a focus on the healthcare sector.  He began his Wall Street career at Lehman Brothers Holdings, Inc., where he spent time in both the New York and Boston offices.  Following this, Mr. Robinson spent 14 years at Leerink Swann (now Leerink Partners, LLC), where he was a Managing Director and Partner.  At Leerink, Mr. Robinson helped establish and build the institutional franchise, and was responsible for covering the firm’s largest accounts, which allowed him to develop deep relationships with many leading healthcare investors.  During his tenure, Mr. Robinson served as “Deal Captain” on most of Leerink’s capital markets transactions, and was the primary liaison between sales and equity capital markets.

Prior to joining LifeSci, Mr. Robinson was the Healthcare Product Specialist and Sector Head at Guggenheim Securities, LLC, where he was responsible for building a research franchise in that sector.  Mr. Robinson earned a Bachelor of Arts degree from Hobart College.  He double-majored in Economics and Russian Area Studies, and played Soccer, Lacrosse, and Squash.

Tim brings over 18 years of investment experience across all healthcare sectors and capitalization ranges, most recently working on life science investments at Sabby Management, Kingdon Capital Management, Millennium Partners and Healthco/SAC Capital.  His extensive buy-side track record, when combined with specialty pharmaceutical sell-side research at CSFB and public accounting experience at Arthur Andersen LLP, provides a well-rounded perspective to the team.

Tim earned a BS with Special Attainments in Commerce from Washington and Lee University and an MBA in Finance and International Business from the Leonard N. Stern School of Business at New York University.  He is a CFA charter holder and completed all CPA qualifications.

Managing Director, Relationship Manager

Joyce Allaire has more than 14 years experience in Institutional Equity Sales. She began her career at Hambrecht & Quist in Boston and post merger worked at JP Morgan in New York. Joyce spent seven years at Leerink Swann & Co. as a Senior Healthcare Sales Specialist where she spearheaded research sales and capital markets initiatives for institutional investors. She brings not only a high level of industry knowledge, but also a broad reach to the buy and sell side constituencies. Joyce received her MBA from Bentley College and graduated from Assumption College with a Bachelor of Arts in Economics and Finance.

Non-Deal Roadshows

Tom Rorke has more than 20 years experience in Institutional Equity Sales. He began his career in the Philadelphia Office of Wertheim and Company. Tom then spent fifteen years at Credit Suisse where he was responsible for Research Sales and Trading in the MidAtlantic, Midwest, Southeast and Canadian Regions. He also Managed Credit Suisse’s MidAtlantic Middle Markets Group for twelve of those years. Prior to joining LifeSci Advisors, Tom worked for two years at Brean Capital where he focused on Health Care Capital Markets. Tom graduated from Wake Forest University with a Bachelor of Arts in Psycholgy and Spanish.
Ed McSorley brings more than 30 years of institutional equity sales experience and a strong book of Street contacts on both the buy side and sell side. He began his institutional equity sales experience at Bache (Prudential Securities) and later worked at Dillon Read, Wasserstein Perella, Hambrecht & Quist, JP Morgan and Citigroup. Ed enlisted in the U.S. Marine Corp at 17 years old and saw service in Vietnam. He received his MBA from Fordham University and graduated from Bryant University with a B.S. in Business Administration.
Mr. Gaul has 20 years of experience in equity sales, including 14 years in institutional healthcare equity sales. Most recently, he was in Equity Research Sales at Vertical Research Group, an independent equity research boutique, and previously served in similar roles at Adams, Harkness & Hill, Canaccord Adams and Leerink Partners. During his career, Mr. Gaul has established and developed relationships with many top-tier buy-side investors and sell-side analysts and bankers. Throughout his career, Mr. Gaul has managed numerous deal and non-deal roadshows in all major financial markets in the United States. He received a Bachelor of Arts degree in English and Economics from Wheaton College.

Casey DeBaecke has more than 25 years of experience in Institutional Equity Sales. She began her career in the Boston Office of First Boston Corporation working in Equity Research. Casey then spent fifteen years at Credit Suisse where she was responsible for Institutional Equity Research Sales in the MidAtlantic Region. Prior to joining LifeSci Advisors, Casey worked for 10 years at UBS in the Institutional Equities Group providing Research Sales coverage to accounts in the MidAtlantic territory. Casey graduated from Boston College with a Bachelor of Science in Finance and a Minor in Asian Studies.

Joe has 20+ years of Capital Markets experience. He started his professional career at Troster Singer, but spent the majority of his time (14 years) at Adams, Harnkess (now Canaccord, Genuity). He ran Equity Trading and Corporate Services at Adams for about 7 years, and was a member of the management team, deal allocation team and compliance committee. He was also a member of the Investment Committee and Trader for Winslow Asset Management (a subsidiary of Adams, now part of Brown Advisory). Joe has a BS in Economics from Bentley College, MBA in Financial Management from Binghamton University, and resides with his wife and three kids in Natick, MA.

Kevin O’Gorman has 20 years of experience as an institutional equity salesperson. Kevin began his career in the New York office of PaineWebber & Co. and spent more than half his career with Buckingham Research, where he was a partner. He brings an extensive network of institutional relationships from the Midwest, greater New York and United Kingdom markets. He joins LifeSci Advisors from Oppenheimer & Co and has an MBA from Fordham Universality and an undergraduate degree in English Literature from the Catholic University of America.

Chuck Padala has spent over 25 years in Institutional Equity Sales & Trading.  He began his career at SunTrust/Robinson Humphrey, where he spent 20 years, and supervised the firm’s NY Sales & Trading desks.  Chuck later joined Brean Capital where he ran the firm’s Equities division and was Head of ECM, followed by two years at Longbow Research as Head of Institutional Sales.  Prior to joining LifeSci Advisors, Chuck served as President of the Securities Traders Association’s NY affiliate and served two consecutive terms on STA’s national Board of Governors.  STA is the largest organization representing professional traders and was founded as a grass roots response to the founding of the SEC in 1934, in order to give market participants a voice in Washington DC.  Chuck graduated with honors from New York University with a Bachelor of Arts in Humanities.

Steve Bilawey MBA- LifeSci Advisors Consultant and Chief Business Officer at Precision Digital health(PDH). PDH delivers enterprise software(SUMMA) for clinical trials and clinical research for CRO’s and the Pharmaceutical industry.  Prior to LifeSci and PDH, Steve spent 13 years working at the boutique healthcare investment bank Leerink Partners on the Institutional equities desk .  He has deep relationships with healthcare/pharmaceutical executives and institutional investors across North America.  He is also involved with Kairos Society as an advisors where he is helping young entrepreneurs develop their businesses.

Non-Deal Roadshows – Private Wealth

Eric Ribner joined LifeSci Advisors as a Vice President in October 2017, focusing on the firm’s Retail Non-Deal Roadshow (NDR) efforts.  Previously, he was a Senior Loan Advisor at Multifunding LLC where he advised businesses on their loan and debt options. Previously, he served as Chief Financial Officer of MetalX. Eric spent more than 20 years working on Wall Street in various capacities, including as an Executive Director of Institutional Sales at Oppenheimer & Co. for 9 years and on the buy-side, first as a Managing Director of Equity Research at NorthStar Capital Funds and then as a Senior Vice President at George Weiss Associates, where he helped manage over $200 million in equities in the financial, industrial, energy and metal sectors. Eric resides in New York and has two children

Corporate Communications

Michael Wood has 20 years experience advising the biotechnology and life science industries, having worked as a sell side analyst, institutional investor and investor relations professional. As a sell-side analyst he worked at Lehman Brothers, UBS and Hambrecht & Quist (now part of JP Morgan). On the buy side, he spent four years working on a healthcare sector fund at Welch Capital Partners in New York. He has also acted as an independent advisor to venture capital firms on PIPE transactions and late stage private investments. Michael is a native of Dublin Ireland and holds an Honors Degree in Microbiology from Trinity College Dublin. He also studied Investor Relations and Corporate Communications at New York University.
Brian Ritchie has over 14 years of healthcare investor communications experience. He focuses on developing, implementing and overseeing investor relations programs for leading medical technology, biotechnology, specialty pharmaceutical, and healthcare services companies. Brian has also worked on a number of financial transactions, including IPOs, follow-on offerings, venture rounds, and M&A agreements. Prior to joining LifeSci, he spent over eight years at FTI Consulting as a Senior Director within the Strategic Communications segment’s Capital Markets Practice and healthcare & life sciences sector. Previously, Brian spent nearly six years at Noonan/Russo Communications, where, in increasingly senior positions, he focused on investor relations for a large variety of life sciences and healthcare companies. He holds a B.S. in communication arts from St. John’s University, where he graduated Cum Laude.
Paul Arndt is an investor relations and corporate communications executive with 20 years of corporate and agency experience. Previously, Paul was Sr. Manager of Investor Relations for Spectrum Pharmaceuticals during which time the company saw a more than 23-fold growth in its market capitalization, an increase in sell-side analyst coverage from two to seven and an increase in institutional ownership from 25% to more than 70% through proactive investor targeting. Prior to Spectrum, he led investor relations and corporate communications for NeoPharm, Inc., where he was responsible for executing long-term investor, corporate, employee, and media relations programs designed to develop and refine core messages to optimize value creation, contributing to a more than 500% increase in market capitalization and a doubling of analyst coverage through several corporate events. Paul also served as an IR consultant at Hill & Knowlton and David A. Noyes & Company. Paul earned his MBA from the Lake Forest Graduate School of Management in Chicago and his Bachelor of Arts in Communications from Quincy University in Quincy, Illinois. He is also a NIRI-National and NIRI-Chicago chapter member, and a recent Officer of the NIRI-Orange County, California chapter.

Monique brings to LifeSci nearly 20 years of Wall Street experience. Her expertise includes roles as both a senior institutional investment analyst with large global asset managers, and as a trusted investor relations advisor providing insight and strategic counsel to senior management teams.

Before joining LifeSci, Monique was a founding partner at Access Capital Advisors, where she partnered with senior management teams to develop investor communications programs tailored
to best convey each client’s value proposition to Wall Street. She and her partner thoughtfully crafted messaging, developed positioning, and targeted key investors.

Prior to her career in investor relations, Monique spent 15 years investing in small-cap healthcare companies as a fundamental research analyst. Her experience encompasses both large
multi-national firms like Deutsche Asset Management and Fidcuciary Trust and small boutique firms like Rochdale Investment Management and Palisade Capital Management. At each firm, Monique provided in-depth fundamental research and analysis to support her
investment recommendations. She was an active member on each firm’s investment committee responsible for firm-wide sector allocation decisions.

Monique began her career at a Washington D.C. industry trade association serving as a liaison between government and industry interpreting government regulations and advising on the
rulemaking process. Her understanding of chemistry and business provided the background to translate highly technical and scientific manufacturing processes for Washington regulators at FDA, EPA, and OSHA.

Monique has her MBA in Finance from New York University Stern School of Business, and dual degrees in Chemistry and German from St. Olaf College. She also holds her Series 7 and Series
66 licenses.

She is an avid triathlete having completed seven Ironman races. When not training, she is diligently in search of the perfect food pairing for the beloved Burgundy wines in her collection.

She and her husband live in Manhattan with their 140 pound English Mastiff, Bella.

Garth Russell has more than 15 years of healthcare IR and corporate communications experience. He has successfully worked with biotechnology and life science companies to establish investor relations capabilities that dovetail with broader corporate communications programs, including public relations and social media. Garth has provided strategic IR counsel to companies through IPOs, secondary offerings, M&A transactions and changes in management. Garth previously worked with KCSA Strategic Communications as Managing Director of Investor Relations, during which his responsibilities included overseeing the firm’s healthcare practice. He holds a B.S. in Marketing from SUNY Plattsburgh. Garth is a NIRI-National and NIRI-New York chapter member.

Glenn Garmont brings to LifeSci nearly two decades of experience, not only in financial communications, but also as a sell-side equity research analyst. Prior to LifeSci, Glenn served as Senior Vice President at Rx Communications LLC, and, before that, Argot Partners, where he developed and executed strategic IR programs for an array of public and private companies across all development stages, in the biotechnology, specialty pharmaceuticals and medical device sectors. He also served as a Vice President on the health care team at ICR.

Before transitioning to investor relations, Glenn spent 12 years as a sell-side equity research analyst, first as a senior associate on multiple highly ranked research teams at Salomon Smith Barney, and then as a senior publishing analyst at boutique banking firms First Albany and ThinkEquity. As a senior analyst, Glenn built his expertise with research focused on health care services, including health care information technology, pharmacy benefit managers, pharmaceutical contract research and sales organizations, disease management, pharmacy automation, drug distribution and managed care.

Glenn earned a B.S. in Finance from Rutgers University and an MBA in Finance from the Stern School of Business at New York University.


Finance Professional

KOL Events

Director of Key Opinion Leader (KOL) Strategy and Management

Morgen Alden is the Director of Key Opinion Leader (KOL) Strategy and Management at LifeSci Partners where she works closely with LifeSci’s research team to plan, organize and execute KOL events, which bring insight and value to the healthcare investment community. Prior to joining LifeSci, Morgen worked as a project manager on the healthcare team at Guidepoint Global, where she fielded KOL meeting requests for 100+ clients on the buyside, sellside, and from corporations in the biotechnology and medtech industries. Her expertise lies in bridging contacts and building mutually beneficial relationships between healthcare professionals and institutional financial investors. Morgen received both her Masters and Bachelor of Arts in Medical Anthropology from the University of Pennsylvania.

Investor Targeting

Managing Director

Angela Qian is a Managing Director at LifeSci Partners, where she oversees the firm’s buy-side and sell-side strategic targeting efforts. She works to bring value to both public and private clients by conducting in-depth comparative peer analyses and broader industry analyses, constructing comprehensive investor relations plans, drafting company board presentations, and assisting in the firm’s corporate communications and access activities. Prior to joining LifeSci Partners, Angela worked at Columbia University Medical Center and the University of Miami Miller School of Medicine. She holds a Bachelor of Arts in Neuroscience from Columbia University.


Account Managers

Managing Director, Head of Europe

Chris has over 20 years of experience in the life sciences industry covering business development, investor relations, public relations, journalism, investing, and molecular neurobiology. He is the founder of BioConfidant Sàrl a Geneva-based strategic consulting firm that helped senior executives achieve their financing and partnering goals. Previously, while at Addex Therapeutics (SIX:ADXN), Chris was a member of the executive management board and held the positions of Head of Investor Relations & Communication (2007-2010) and Director Business Development (2010-2013). He co-founded the Alpine Institute for Drug Discovery in 2013, a not-for-profit social enterprise whose mission is to help commercialize academic discoveries. In addition, Chris worked as: a journalist for the leading biotechnology trade publication BioCentury (2001-2007); an Associate at Casdin Life Science Partners (later Cooper Hill), a NYC-based biotechnology hedge-fund (1997-2000); and a molecular neurobiologist studying drug dependence at The Rockefeller University (1993-1997), where he co-authored twelve peer-reviewed publications. Chris holds a BA in English Literature from Yale University, where he also completed pre-medical studies.

Account Manager

Hans is an investor relations and corporate communications executive with over 25 years of corporate and agency experience. He has been involved in shaping the communication strategies for private financings, M&A, partnering, and IPOs, which in aggregate exceed $1.5 billion. Recently he was Head of Investor Relations & Corporate Communications of Symetis, which was acquired by Boston Scientific for EUR 425 million. He held the same position at Amsterdam Molecular Therapeutics/uniQure at the time of the company’s first IPO in 2007, and from 2000 until 2007 at IsoTis OrthoBiologics, managing the Company’s IPO, M&A transactions, and its three stock market listings in Amsterdam, Zurich, and Toronto. At the start of his career, Hans worked with Amgen International for five years, as it was establishing its footprint outside the U.S. Hans has BA degrees in Portuguese Linguistics & Literature, the Philosophy of Law, and Translation Sciences, and an MA in Italian Literature & Linguistics from the University of Amsterdam. He is fluent in Dutch, English, Italian, and French. A Dutch national, Hans is based in Switzerland, and is an avid open water swimmer.

Non-Deal Roadshows

Managing Director & Head of European Corporate Access

Niki started in institutional equity sales almost 20 years’ ago, initially in US equity sales at Cowen and JP Morgan, and then specialised in US healthcare stocks & later also European Healthcare stocks at JP Morgan and Fortis Bank, with a particular focus on Biotechnology companies at the latter. In 2009 she founded Aetia Ltd, a UK based healthcare specialist financial services firm offering capital raising and investor access services to private and public healthcare companies around the world, further developing her long-standing relationships with the healthcare investment community across Europe. During her career, Niki has managed numerous deal and non-deal roadshows across the UK and Europe and has a successful track record raising capital for a wide range of both public and private global life science companies at various stages of development. Prior to her investment banking career, Niki worked at Pricewaterhouse Coopers. She has a BSc in Business Management and Languages from Kings’ College, London.

Managing Director, Switzerland

Floriane, is managing director of Investment Connections (Geneva, Switzerland), which she founded in 2004. Her firm has developed close working relationships with a broad spectrum of European investors, including generalists, family offices, high net worth individuals and institutional investors including healthcare specialists. Previously, Floriane worked with European Investor Relations SA (now Voxia), where she was responsible for the internal management of the EIR team as well as assisting clients directly with their European roadshows. Floriane holds a Master Degree in Business Management from HEC (Hautes Etudes Commerciales) – University of Geneva.

Managing Director, France & Germany

Anne has over 20 years’ experience in institutional equity sales. She started her career at Banque Harwanne and joined the Banque NSM (ABN AMRO Group) where she became head of Institutional Sales Europe. In 2004, she founded Finapsis an independent advisory firm specialising in fundraisings for listed and non listed companies, where she completed numerous transactions in healthcare and software. Anne graduated from the Reims Management School.

Managing Director

Norma has over 20 years’ experience in institutional equity sales and has been heavily involved in marketing PIPEs, IPOs and secondary offerings to European specialist healthcare & tech funds. For the last 8 years Norma was healthcare specialist sales on the US institutional equity desk at Oppenheimer in London, covering UK, Swiss and German specialist investors. She spent the first half of her career on the US equity sales desk at CIBC in London where she had overall responsibility for Swiss investors and managed a team selling the firm’s US equity research product into Switzerland while personally focusing on healthcare and technology stocks. Norma earned a BSc in Financial Economics from University of London.


Account Managers

Managing Director, Israel

Moran brings over 15 years of Investor Relations experience, having worked with Israel’s largest and most prominent private and publicly traded companies. Prior to joining LifeSci Advisors, Mrs. Meir-Beres was a senior account executive at KM Investor Relations, Israel’s first and largest IR firm, where she provided companies from a wide range of sectors ongoing investor and financial media relations advice, as well as advisory services related to public and private securities offerings, mergers and acquisitions, and crisis management. Prior to joining KM, Ms Meir-Beres was part of the IR team at Teva (NYSE: TEVA), Israel’s largest healthcare company. Moran earned her BA and Master Degree in Law from Bar-Ilan University in Israel.

Non-Deal Roadshows – Institutional and Private Wealth

Meirav brings over 11 years of Investor Relations experience, advising local, dual, and international listed Israeli public companies across industries, with expertise in Life Sciences and Bio-tech companies. Previously, she was a Senior Account Executive at KM Investor Relations, Israel’s first and leading IR firm. In the life-science industry, Meirav has advised companies like BioLineRx, Compugen, Exalenz, Check-Cap, Alcobra, BioBlast, Medigus, Therapix Biosciences, and others, creating, executing and maintaining their IR and Financial media strategy and relationships with the Israeli capital market and financial media. This also included targeting and NDR’s, advisory services related to public and private securities offerings, and crisis management. In her position as a Senior Account Executive at KM Investor Relations, Meirav has formed and managed a first-time designated Family Office and HNW forum specializing in HNW activity and events. Working closely with the Israeli Capital market, Meirav has long-term relationships with Institutional investors, Strategic investors; Private Equity and Hedge funds, Proprietary traders as well as Family Offices and HNW individuals. Meirav holds a Bachelor of Laws (LL.B) from Tel Aviv University and a Master of Business Administration (MBA) from Bar Ilan University in Israel.


Managing Director

Managing Director, Head of Asia

Greg Meiselbach joins LifeSci with a track record of building successful international outreach and business development programs for western companies in emerging markets. Greg founded The Shelburne Group, an advisory firm serving companies on matters of international investor relations, government relations, market entry, stakeholder engagement, and partner development. Greg was also Director for International Affairs at the Biotechnology Innovation Organization (BIO) for five years. In his role, he managed BIO’s international government affairs portfolio for Asia Pacific and worked with BIO’s members to craft international engagement strategies to promote member companies’ business interests abroad. Prior to this, while based out of Singapore, Greg built and managed the Asia Pacific portfolio of Frontier Strategy Group’s Expert Advisory Network, a broad network of in-market experts, professionals, and former officials who supported Frontier Strategy Group’s clients’ expansion into emerging markets. Greg holds a B.A. in Political Science from Tufts University in Medford, MA and speaks conversational Mandarin.